

THE PROBLEM

Doctors rely on patient self-reported data and subjective clinical exams to manage and treat chronic neurological disorders, a significant economic burden of \$1.7T in the US and Europe alone. The lack of a reliable biomarker leads to poor patient outcomes with years spent trying to find the right treatment. Pharmaceutical companies also rely on the same self-reported data leading to stagnant treatment innovations and no significant improvement in outcomes in the last 30 years.

1B

Person with Neurological Disorders Worldwide

1 in 3

Person will develop Neurological Disorder

1st

Neurological Disorders are the leading cause of disability

2nd

Neurological Disorders are the second leading cause of death

THE SOLUTION

- Eysz believes eye-movements are a better biomarker to assess brain health and are building a digital health platform to objectively measure symptoms across neurological disorders starting with epilepsy – a disorder characterized by recurrent seizures. Our AI-based clinical decision support software analyzes eye-movements from off-the-shelf eye-tracking systems to objectively measure consciousness, cognition, and mood.

LARGE INITIAL MARKET

- US Provider Market Opportunity: \$1.7B
- Competition: Seizure counting using wearables (<20% of seizure types) or EEG-based wearables (EEG has not been shown to improve outcomes)
- Opportunity to expand usage throughout the care continuum and other neurological indications
- Business Model: SaaS for providers, fixed fee for pharma

POTENTIAL BENEFITS

- Optimize diagnosis and treatment, in-clinic and remote
- Decrease costs related to unnecessary testing and hospitalizations
- Increase access to neuropsych testing
- Accelerate development of new therapies
- Predict most effective treatment

MILESTONE DRIVEN

- ✓ Successful Proof of Concept Study under IRB
- ✓ Market Validation thru NSF/NIH I-Corps (n >200)
- ✓ Confirmed Reg Pathway, Study via FDA Pre-Sub
- ✓ Multi-center Clinical Study (N=166)
- ✓ Prototype and Feedback Received

FUNDRAISING

- We are currently **raising \$7.5M USD**
- Previously Raised: \$1.3M in Grants (NIH/NSF) and \$1.9M via 1st SAFE Round (UCB Pharma, Sand Hills Angels, Plug and Play)

We expect to use the proceeds to help us expand our team and achieve our next milestones, specifically: Validation Study, Reimbursement Coverage, FDA Clearance, and initial Revenue.

TEAM



RACHEL KUPERMAN, MD
Founder & CEO

UCSF Faculty, Led Peds Epilepsy Program for 10+ years



BIKRAMJIT SARKAR, PhD
Co-Founder

15+ Years Computer Science, AI/ML, Signal Processing Experience



PARTH AMIN
Co-Founder

15+ Years Medical Device Experience: Business Development - Alliances, Prod & Project Mgmt



NON-DILUTIVE FUNDING and AWARDS

- 2021 NSF SBIR Phase 1 Grant (\$256K)
- 2021 NIH Diversity Supplement Grant (\$138K)
- 2020 NIH NINDS SBIR Phase 1 Grant (\$656K)
- 2020 Greenwich Biosciences Grant (\$25K)
- 2019 CTIP - FDA Sponsored Ped. Dev. Accelerator (\$50K)
- 2019 Epilepsy Foundation Shark Tank - 1st Place (\$150K)

COMPANY INFO

- Founded in 2018 in Bay Area, California
- Advisors: Robert Fisher, MD PhD; Hal Blumenfeld, MD PhD; Peter Milford, PhD; Nicole Napier PsyD; Board of Directors: Randy Berholtz JD, MBA; Rachel Kuperman, MD
- Contact Info: rkuperman@eyszlab.com
- Website: www.eyszlab.com